2018 MIPS Measure #442: Persistence of Beta-Blocker Treatment After a Heart Attack

Measure Type High Priority Measure? NQS Domain
Process No Effective Clinical Care
Data Submission Method(s)
Registry

Measure Description

The percentage of patients 18 years of age and older during the measurement year who were hospitalized and discharged from July 1 of the year prior to the measurement year to June 30 of the measurement year with a diagnosis of acute myocardial infarction (AMI) and who were prescribed persistent beta-blocker treatment for six months after discharge

Instructions

This measure is to be submitted a minimum of once per performance period for patients seen during the performance period. This measure may be submitted by eligible clinicians who perform the quality actions described in the measure based on the services provided and the measure-specific denominator coding.

NOTE: Include only patients that are discharged through June 30 of the performance period. This will allow the evaluation of at least 180 days after discharge within the performance year.

Measure Submission:

The listed denominator criteria is used to identify the intended patient population. The numerator options included in this specification are used to submit the quality actions allowed by the measure. The quality-data codes listed do not need to be submitted for registry-based submissions; however, these codes may be submitted for those registries that utilize claims data.

Denominator

Patients 18 years of age and older as of December 31 of the measurement year who were hospitalized and discharged from July 1 of the year prior to the measurement year to June 30 of the measurement year with diagnosis of AMI

Table PBH-D: Medications to Identify Exclusions (History of Asthma)

Description

 

Prescription

 

Bronchodilator combinations

Albuterol-ipratropium Budesonide-formoterol

Fluticasone-salmeterol Mometasone-formoterol

 

Inhaled corticosteroids

Beclomethasone

Budesonide

Ciclesonide

Flunisolide 

Fluticasone 

Fluticasone CFC free

Mometasone

 

Denominator Criteria (Eligible Cases):
Patients aged ≥ 18 years within measurement year

AND

Discharge(s) for AMI between July 1 of the year prior to the measurement year to June 30 of the measurement period: G9798

AND

Patient encounter(s) during performance period (CPT): 99201, 99202, 99203, 99204, 99205, 99212, 99213, 99214, 99215, 99304, 99305, 99306, 99307, 99308, 99309, 99310, 99324, 99325, 99326, 99327, 99328, 99334, 99335, 99336, 99337, 99341, 99342, 99343, 99344, 99345, 99347, 99348, 99349, 99350

AND NOT

DENOMINATOR EXCLUSIONS: 

Patients with a diagnosis of Asthma, COPD, Obstructive chronic bronchitis, Chronic respiratory conditions due to fumes and vapors, Hypotension, heart block >1 or sinus bradycardia any time during the patient’s history through the end of the measurement period: J45.20, J45.21, J45.22, J45.30, J45.31, J45.32, J45.40, J45.41, J45.42, J45.50, J45.51, J45.52, J45.901, J45.902, J45.909, J45.990, J45.991, J45.998, I44.1, I44.2, I44.4, I44.5, I44.60, I44.69, I44.7, I45.0, I45.10, I45.19, I45.2, I45.3, I45.6, I49.5, I95.0, I95.1, I95.2, I95.3, I95.81, I95.89, I95.9, R00.1, J68.4, J44.0, J44.1, J44.9, T44.7X5A, T44.7X5D, T44.7X5S

OR

Patients with a medication dispensing event indicator of a history of asthma any time during the patient’s history through the end of the measure period: G9799

OR

Patients who are identified as having an intolerance or allergy to beta-blocker therapy: G9800

OR

Hospitalizations in which the patient was transferred directly to a non-acute care facility for any diagnosis: G9801

OR

Patients who use hospice services any time during the measurement period: G9802

Numerator

Patients who had a 180-day course of treatment with beta-blockers post discharge Table: Beta-Blocker Medications

Description

Prescription

Noncardioselective betablockers

Carvedilol

Labetalol

Nadolol

Penbutolol

Pindolol

Propranolol

Timolol Sotalol

Cardioselective beta-blockers

Acebutolol Atenolol

Betaxolol Bisoprolol

Metoprolol Nebivolol

Antihypertensive combinations

Atenolol-chlorthalidone

Bendroflumethiazide-nadolol

Bisoprolol-hydrochlorothiazide

Hydrochlorothiazide-metoprolol Hydrochlorothiazide-propranolol

Numerator Options:

Performance Met:

Patient prescribed a 180-day course of treatment with betablockers post discharge for AMI (G9803)

OR

Performance Not Met:  

Patient was not prescribed a 180-day course of treatment with beta-blockers post discharge for AMI (G9804)

Stay up to date with the latest news regarding MACRA and MIPS.

The Healthmonix Advisor is a free weekly news source, connecting you to the latest updates in the value-based care industry.